

# Catia Marzolini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3502737/publications.pdf>

Version: 2024-02-01

81  
papers

2,172  
citations

279487

23  
h-index

253896

43  
g-index

85  
all docs

85  
docs citations

85  
times ranked

2455  
citing authors

#	ARTICLE	IF	CITATIONS
1	Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 579-584.	2.3	15
2	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). <i>International Journal of Epidemiology</i> , 2022, 51, 33-34j.	0.9	69
3	Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 568-573.	1.3	4
4	Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 492-499.	1.3	7
5	Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years. <i>Journal of Infectious Diseases</i> , 2022, 225, 1581-1591.	1.9	3
6	Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1044-1046.	2.8	13
7	Fluvoxamine for the treatment of COVID-19. <i>The Lancet Global Health</i> , 2022, 10, e331.	2.9	9
8	Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions. <i>Annals of Internal Medicine</i> , 2022, 175, 744-746.	2.0	35
9	Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021. <i>HIV Medicine</i> , 2022, 23, 849-858.	1.0	57
10	Magnitude of Drug-Drug Interactions in Special Populations. <i>Pharmaceutics</i> , 2022, 14, 789.	2.0	5
11	Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection. <i>Clinical Pharmacokinetics</i> , 2022, 61, 339-346.	1.6	1
12	Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2022, 61, 619-635.	1.6	9
13	Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 1191-1200.	2.3	122
14	Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors. <i>Clinical Infectious Diseases</i> , 2021, 73, e2145-e2152.	2.9	9
15	COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 212-213.	1.1	20
16	Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 458-470.	1.1	12
17	Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 471-484.	2.3	10
18	Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19. <i>Drug Safety</i> , 2021, 44, 255-257.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2021, 60, 379-390.	1.6	4
20	Prescribing in COVID-19 patients: Should we take into account inflammation?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 719-721.	1.1	0
21	Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 979-987.	0.8	2
22	Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1025-1029.	2.3	8
23	Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1231-1239.	2.3	13
24	Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine. <i>Clinical Pharmacokinetics</i> , 2021, 60, 835-853.	1.6	50
25	Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance. <i>Microorganisms</i> , 2021, 9, 1094.	1.6	21
26	Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre. <i>Global Cardiology Science &amp; Practice</i> , 2021, 2021, e202111.	0.3	3
27	Coronary Artery Disease-Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 1597-1604.	2.9	5
28	Recognition and management of clinically significant drug-drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: a prospective questionnaire-based study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2681-2689.	1.3	2
29	Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient—a case report and review of the literature. <i>AIDS Research and Therapy</i> , 2021, 18, 56.	0.7	4
30	Polypharmacy and risk of admission to hospital in people ageing with HIV: what is the contribution of drug-drug interactions?. <i>The Lancet Healthy Longevity</i> , 2021, 2, e606-e607.	2.0	1
31	Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. <i>Drugs in R and D</i> , 2021, 21, 9-27.	1.1	31
32	Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 758-764.	1.3	14
33	Sex-related pharmacokinetic differences with aging. <i>European Geriatric Medicine</i> , 2021, , 1.	1.2	2
34	Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly. <i>Clinical Pharmacokinetics</i> , 2020, 59, 383-401.	1.6	29
35	Polypharmacy and Drug-Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 353-362.	2.9	52
36	Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. <i>Aids</i> , 2020, 34, 103-108.	1.0	18

#	ARTICLE	IF	CITATIONS
37	Drug–Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1217-1236.	1.6	9
38	Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3417-3424.	1.3	30
39	Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study. <i>Journal of Infectious Diseases</i> , 2020, 224, 1198-1208.	1.9	5
40	Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3084-3086.	1.3	43
41	Cobicistat: A case of mislabelled drug–drug interaction risk?. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 834-836.	1.1	7
42	Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	50
43	Development and validation of a multiplex UHPLC–MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegrovir, cabotegravir, doravirine, and rilpivirine in people living with HIV. <i>Journal of Mass Spectrometry</i> , 2020, 55, e4506.	0.7	22
44	New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. <i>Hepatology</i> , 2020, 71, 1831-1844.	3.6	16
45	The challenge of HIV treatment in an era of polypharmacy. <i>Journal of the International AIDS Society</i> , 2020, 23, e25449.	1.2	107
46	Real-life management of drug–drug interactions between antiretrovirals and statins. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1972-1980.	1.3	8
47	Aging does not impact drug–drug interaction magnitudes with antiretrovirals. <i>Aids</i> , 2020, 34, 949-952.	1.0	2
48	Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1037-1048.	1.6	5
49	Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1553-1565.	1.6	24
50	Current Challenges and Solutions in Research and Clinical Care of Older Persons Living with HIV: Findings Presented at the 9th International Workshop on HIV and Aging. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 985-998.	0.5	12
51	UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug–drug interactions studies in people living with HIV. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1125, 121733.	1.2	10
52	Mortality from suicide among people living with HIV and the general Swiss population: 1988–2017. <i>Journal of the International AIDS Society</i> , 2019, 22, e25339.	1.2	24
53	Prescribing issues in older adults living with HIV: thinking beyond drug–drug interactions with antiretroviral drugs. <i>Therapeutic Advances in Drug Safety</i> , 2019, 10, 204209861988012.	1.0	14
54	Prescribing issues in elderly individuals living with HIV. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 643-659.	1.3	20

#	ARTICLE	IF	CITATIONS
55	Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2022-2032.	1.1	7
56	Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2468-2470.	1.3	3
57	A Comprehensive Framework for Physiologically-Based Pharmacokinetic Modeling in Matlab. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 444-459.	1.3	32
58	Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz531.	0.4	38
59	Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes. <i>Clinical Pharmacokinetics</i> , 2019, 58, 483-501.	1.6	48
60	Mechanisms of Drug Interactions II: Transport Proteins. , 2018, , 49-85.		3
61	Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	17
62	Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in the early and late postgastric bypass surgery periods. <i>Aids</i> , 2018, 32, 1903-1905.	1.0	7
63	Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. <i>Clinical Mass Spectrometry</i> , 2018, 8, 8-20.	1.9	10
64	HIV and Aging - Perhaps Not as Dramatic as We Feared?. <i>Gerontology</i> , 2018, 64, 446-456.	1.4	7
65	Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2835-2838.	1.1	15
66	Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2574-2577.	1.3	8
67	Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. <i>Clinical Pharmacokinetics</i> , 2017, 56, 409-420.	1.6	18
68	Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection. <i>PLoS ONE</i> , 2017, 12, e0173509.	1.1	29
69	Privacy-preserving genomic testing in the clinic: a model using HIV treatment. <i>Genetics in Medicine</i> , 2016, 18, 814-822.	1.1	36
70	Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1755-1758.	1.3	102
71	Etravirine: a good option for concomitant use with chemotherapy for Hodgkin's lymphoma. <i>International Journal of STD and AIDS</i> , 2015, 26, 212-214.	0.5	5
72	Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1203-1217.	1.5	11

#	ARTICLE	IF	CITATIONS
73	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naïve adults. <i>Aids</i> , 2015, 29, 193-200.	1.0	13
74	Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu040.	0.4	61
75	Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. <i>Clinical Pharmacokinetics</i> , 2013, 52, 583-592.	1.6	47
76	The Brain Entry of HIV-1 Protease Inhibitors Is Facilitated When Used in Combination. <i>Molecular Pharmaceutics</i> , 2013, 10, 2340-2349.	2.3	20
77	Maternal antiretroviral prophylaxis and breastfeeding. <i>Antiviral Therapy</i> , 2012, 17, 1503-1506.	0.6	3
78	Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy. <i>PLoS ONE</i> , 2012, 7, e29186.	1.1	21
79	Ageing with HIV: medication use and risk for potential drug-drug interactions. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2107-2111.	1.3	131
80	Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2010, 15, 413-423.	0.6	172
81	Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 20-30.	2.3	231